olodaterol

Ligand id: 7543

Name: olodaterol

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: olodaterol

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 4
Hydrogen bond donors 4
Rotatable bonds 7
Topological polar surface area 100.05
Molecular weight 386.18
XLogP 1.79
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Olodaterol was approved by the FDA in July 2014 as an inhalation medication for the treatment of chronic obstructive pulmonary disease (COPD). Phase II trials have also been conducted in patients with asthma (see NCT01013753).
This drug has been further assessed in clinical trials in combination with the muscarinic antagonist tiotropium bromide (also a bronchodilator).
In May 2015 the US FDA approved a fixed-dose combination of tiotropium bromide and olodaterol (Stiolto Respimat®) as 'a long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema' Drugs.com.
Click here to view a full list of associated trials registered with ClinicalTrials.gov.
Mechanism Of Action and Pharmacodynamic Effects
Olodaterol is a long acting β-adrenoceptor agonist (LABA) acting on β2-ARs in the lung to cause bronchodilation which improves airway function. Olodaterol appears to have low intrinsic β1-AR action, thereby limiting cardiac side effects [1].
External links